Results 31 to 40 of about 2,118 (199)
Platelet transfusions have contributed to the revolutionary modern treatment of hypoproliferative thrombocytopenia. Despite the long-term application of platelet transfusion in therapeutics, all aspects of their optimal use (i.e., in cases of ABO and/or ...
Serena Valsami +4 more
doaj +1 more source
Efficacy of apheresis platelet transfusion in 310 patients with haematological diseases
Objective To observe the effect of platelet transfusion in inpatients with haematological diseases, analyze the possible causes of platelet transfusion refractoriness (PTR), in order to further improve the efficacy of platelet transfusion.
Shisong YOU +5 more
doaj +1 more source
Management of Patients Refractory to Platelet Transfusion
Abstract Objective. —To present a current assessment and practical approach to the diagnosis and management of patients who are refractory to platelet transfusions. Design. —A task force was convened by the College of
Ronald A, Sacher +5 more
openaire +2 more sources
Background: This study was designed to determine the prevalence and assess the risk factors responsible for platelet transfusion refractoriness in hemato-oncological patients. Materials and Methods: The study included 30 patients.
Vijay Kumawat +3 more
doaj +1 more source
ABSTRACT Chronic liver disease (CLD)‐related thrombocytopenia can limit the feasibility of invasive procedures. Recombinant human thrombopoietin (rhTPO) has demonstrated a favorable safety profile without hepatotoxicity. We evaluated the efficacy and safety of rhTPO in patients with CLD‐related thrombocytopenia who were undergoing elective invasive ...
Yifan Han +45 more
wiley +1 more source
[Objective] To evaluate the performance of platelet efficacy score (PEscore) in predicting platelet transfusion efficacy in hematological patients. [Methods] A total of 485 patients with hematological diseases, including 298 males (62.09±15.45 years) and
LI Jun +4 more
doaj +1 more source
ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study.
Antonio M. Risitano +52 more
wiley +1 more source
[Objective] To compare and analyze the efficacy of platelet transfusion in patients with different doses, and to analyze the risk factors for platelet transfusion refractoriness.
ZHU Jianling +5 more
doaj +1 more source
ABSTRACT Heterozygous germline variants in CBL disrupt its function as a negative regulator of the Ras/MAPK pathway, classically predisposing to Juvenile myelomonocytic leukemia (JMML) and moyamoya. We describe two affected siblings carrying a paternally inherited CBL variant (c.1210 T> C, p.
Michal Bar‐Hakim +12 more
wiley +1 more source
Platelet transfusion refractoriness is a serious clinical concern that complicates the management of thrombocytopenic patients. Previous studies have suggested a potential role for both complement and platelet activation based on in vitro analyses of ...
Alexander Åkesson +7 more
doaj +1 more source

